KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma

被引：0
|
作者：
Atkins, Michael B.
Carlino, Matteo S.
Hill, Andrew G.
McNeil, Catriona M.
Long, Georgina V.
Atkinson, Victoria
Cebon, Jonathan S.
Jameson, Michael B.
Hwu, Wen-Jen
Thompson, John A.
Anderson, James
Moreno, Blanca Homet
Ibrahim, Nageatte
Ribas, Antoni
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT065
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).
    Weber, Jeffrey S.
    Larkin, James M. G.
    Schadendorf, Dirk
    Wolchok, Jedd D.
    Wagstaff, John
    Dummer, Reinhard
    Hogg, David
    Guidoboni, Massimo
    Sosman, Jeffrey Alan
    Chmielowski, Bartosz
    Gerritsen, Winald
    Bhore, Rafia
    Walker, Dana
    Gonzalez, Rene
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] A phase I trial of panobinostat with ipilimumab in advanced melanoma.
    Khushalani, Nikhil I.
    Markowitz, Joseph
    Eroglu, Zeynep
    Giuroiu, Iulia
    Ladanova, Viktoriya
    Reiersen, Pamela
    Rich, Jeani
    Thapa, Ram
    Schell, Michael J.
    Sotomayor, Eduardo M.
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
    Ascierto, P. A.
    Ferrucci, P. F.
    Stephens, R.
    Del Vecchio, M.
    Atkinson, V.
    Schmidt, H.
    Schachter, J.
    Queirolo, P.
    Long, G. V.
    Di Giacomo, A. M.
    Svane, I.
    Lotem, M.
    Bar-Sela, G.
    Couture, F.
    Mookerjee, B. P.
    Ghori, R.
    Ibrahim, N.
    Moreno, B. Homet
    Ribas, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 442 - 442
  • [34] Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.
    Sendur, Mehmet Nahit
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Park, Keunchil
    Lee, Dae Ho
    Cicin, Irfan
    Yumuk, Perran Fulden
    Orlandi, Francisco J.
    Leal, Ticiana A.
    Molinier, Olivier
    Soparattanapaisarn, Nopadol
    Langleben, Adrian
    Califano, Raffaele
    Medgyasszay, Balazs
    Hsia, Te-Chun
    Otterson, Gregory Alan
    Xu, Lu
    Burke, Thomas A.
    Samkari, Ayman
    Boyer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
    Long, Georgina V.
    Hamid, Omid
    Hodi, F. Stephen
    Lawrence, Donald P.
    Atkinson, Victoria
    Starodub, Alexander
    Carlino, Matteo S.
    Fisher, Rosalie Anne
    Miller, Wilson H.
    Maio, Michele
    Butler, Marcus
    Queirolo, Paola
    Ferrucci, Pier Francesco
    Petrella, Teresa M.
    Schachter, Jacob
    Huang, Yingjie
    Diede, Scott J.
    Ebbinghaus, Scot
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Pembrolizumab plus Chemoradiotherapy for locally advanced Cervical Cancer - the prospective, randomized KEYNOTE-A18 Phase 3 Trial
    Trommer, Maike
    Gaasch, Aurelie
    Corradini, Stefanie
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (11) : 994 - 996
  • [37] Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
    Patnaik, Amita
    Socinski, Mark A.
    Gubens, Matthew A.
    Gandhi, Leena
    Stevenson, James
    Bachman, Robert D.
    Bourque, Jennifer
    Ge, Joy Yang
    Im, Ellie
    Gadgeel, Shirish M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
    Postow, Michael
    Chesney, Jason
    Pavlick, Anna
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey
    Agarwala, Sanjiv
    Shaheen, Montaser
    Ernstoff, Marc
    Minor, David
    Salama, April
    Taylor, Matthew
    Ott, Patrick
    Jiang, Joel
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd
    Hodi, F. Stephen
    CANCER RESEARCH, 2016, 76
  • [39] Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
    Zakharia, Yousef
    McWilliams, Robert R.
    Rixe, Olivier
    Drabick, Joseph
    Shaheen, Montaser F.
    Grossmann, Kenneth F.
    Kolhe, Ravindra
    Pacholczyk, Rafal
    Sadek, Ramses
    Tennant, Lucinda L.
    Smith, Christopher M.
    Kennedy, Eugene P.
    Link, Charles J., Jr.
    Vahanian, Nicholas N.
    Yu, Jiayi
    Shen, Steven S.
    Brincks, Erik L.
    Rossi, Gabriela R.
    Munn, David
    Milhem, Mohammed
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
  • [40] Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study
    Hamid, O.
    Chin, K.
    Li, J.
    Neyns, B.
    Linette, G.
    Negrier, S.
    Lutzky, J.
    Hoos, A.
    Wolchock, J.
    Lebbe, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345